
The recent U.S. executive order on psychedelics serves as a major catalyst for the sector, making clinical-stage leaders Atai Life Sciences (ATAI), Cybin (CYBN), and Compass Pathways (CMPS) high-conviction buys for regulatory momentum. Investors should maintain a bullish bias on the NASDAQ, as low institutional positioning and forced buying from trend-following funds (CTAs) are expected to drive the "pain trade" higher. The implementation of ESLR Reform acts as a "light QE," injecting roughly $1 trillion in liquidity into the repo market and providing a significant tailwind for risk assets. While Brent Crude may reach $100/barrel, the U.S. economy’s energy efficiency makes this price manageable; therefore, investors should avoid "doom" narratives and use geopolitical dips as entry points. Monitor the ISM index for readings above 55, which would confirm robust economic expansion and support continued growth in U.S. equities despite late-cycle risks.
The discussion highlighted a significant positive shift for the psychedelics industry following political developments in the U.S., specifically an executive order delivered by Donald Trump after a meeting with Joe Rogan.
Despite the ongoing conflict involving Iran and the Strait of Hormuz, the analysts argue that the Western economy is more resilient to high oil prices than in previous decades.
The market is currently in what the analysts call a "hated rally," characterized by low participation from institutional investors despite rising prices.
A technical but critical driver for the current market strength is the change in banking regulations and dollar liquidity.
The U.S. economy is showing surprising strength despite high interest rates and geopolitical tensions.

By @realvisionfinance
We arm you with the knowledge, the tools, and the network to succeed on your financial journey.